arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

FENNEC PHARMACEUTICALS INC.

FENC
$11.58 ▲ +0.72 (+6.63%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
30 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bearish
auto_awesome

Analytical Summary

FENNEC PHARMACEUTICALS INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $330.9M
Dividend Yield
Revenue Growth -6.1%
Op. Margin -14.1%
ROIC -17.9%
FCF / Share $-0.44
Trailing P/E
Price / Book 11.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

30-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$44.64M
↓ -6.1%
Net Income Profit after all expenses
$-9.74M
↓ -2134.2%
Operating Margin Operating profit as % of sales
-14.1%
↓ -360.5% 12th
FCF / Share Free cash flow per share
$-0.44
↓ -144.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
10
Returns
24
Financial Health
40
Cash Quality
75

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 30 years · 117 quarters